Persistent infection with human papillomaviruses (HPV) can cause cervical cancer, which is the fourth most common cancer in women worldwide. Most cases occur in low- and middle-income countries (LMIC) where resource constraints pose significant barriers to prevention. Prophylactic HPV vaccines have demonstrated strong protection against persistent HPV infection, cervical pre-cancerous lesions and cancer. These vaccines are currently recommended as 2-dose HPV vaccine schedule separated by 6 months in boys and girls under the age of 15, although emerging data suggest that a single dose of the HPV vaccines offers similarly strong protective antibody responses. At present, very little is known about the characteristics of the antibody response following reduced-dose HPV vaccine schedules. In this study, we examined the antibody profiles of adolescent Fijian girls who previously received 1 or 2 doses of 4vHPV (Gardasil®, Merck Inc.) 6 years earlier, compared to those who received 3 doses. A prospective cohort study was undertaken in 200 Fijian girls (aged 15-19 years at the commencement of the study) who previously received 0, 1, 2 or 3 doses of 4vHPV in 2008-2009. Blood was taken before and 28 days following a booster dose of 2vHPV (Cervarix®, GSK). HPV16/18-specific antibody subclasses (total IgG, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2 and IgM) in serum were measured using a HPV multiplex immunoassay on a subset of the study samples, with equal numbers of participants in each dose group (N=80, 20/group). After 6 years, there were no significant differences in antibody profiles between the 2- and 3-dose groups. HPV16/18-specific geometric mean FI were significantly lower for the 1-dose group compared to the 2-dose group in terms of IgG (HPV16; p=0.0006, HPV18; p=0.0071 respectively), IgG1 (HPV16; p=0.0246), and IgA1 (HPV16; p=0.0042). No significant differences were found between these groups for IgM, IgA2, IgG2, IgG3 and IgG4. Post-2vHPV, HPV16/18-specific antibody profiles were similar between groups who previously received 1, 2 or 3 doses of 4vHPV. These data suggest that 1-dose vaccine schedules may induce functional antibody responses similar to 2 or 3 doses, and provide immunological evidence supporting 1-dose HPV vaccine schedules in LMICs.